Institute of Biological Sciences (ISSB-P), Mohammed VI Polytechnic University (UM6P), 43150 Ben-Guerir, Morocco.
Institute of Biological Sciences (ISSB-P), Mohammed VI Polytechnic University (UM6P), 43150 Ben-Guerir, Morocco.
Biomed Pharmacother. 2022 Jul;151:113126. doi: 10.1016/j.biopha.2022.113126. Epub 2022 May 26.
Rheumatoid arthritis (RA) is one of more than 100 types of arthritis. This chronic autoimmune disorder affects the lining of synovial joints in about 0.5% of people and may induce severe joints deformity and disability. RA impacts health life of people from all sexes and ages with more prevalence in elderly and women people. Significant improvement has been noted in the last two decades revealing the mechanisms of the development of RA, the improvement of the early diagnosis and the development of new treatment options. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) remain the most known treatments used against RA. However, not all patients respond well to these drugs and therefore, new solutions are of immense need to improve the disease outcomes. In the present review, we discuss and highlight the recent findings concerning the different classes of RA therapies including the conventional and modern drug therapies, as well as the recent emerging options including the phyto-cannabinoid and cell- and RNA-based therapies. A better understanding of their mechanisms and pathways might help find a specific target against inflammation, cartilage damage, and reduce side effects in arthritis.
类风湿关节炎（RA）是 100 多种关节炎中的一种。这种慢性自身免疫性疾病影响大约 0.5%人群的滑膜关节衬里，可能导致严重的关节畸形和残疾。RA 影响所有性别和年龄的人群的健康生活，在老年人和女性中更为普遍。在过去二十年中，人们对 RA 的发病机制、早期诊断的改善以及新的治疗选择的发展有了显著的认识。非甾体抗炎药（NSAIDs）、皮质类固醇和疾病修饰抗风湿药（DMARDs）仍然是针对 RA 最常用的治疗方法。然而，并非所有患者对这些药物都有良好的反应，因此，非常需要新的解决方案来改善疾病结局。在本综述中，我们讨论并强调了关于 RA 治疗的不同类别，包括传统和现代药物治疗，以及最近出现的选择，包括植物大麻素和基于细胞和 RNA 的治疗。更好地了解它们的机制和途径可能有助于找到针对炎症、软骨损伤的特定靶点，并减少关节炎的副作用。
